La chaîne d'options affiche les données clés des options sur actions de Calidi Biotherapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Calidi Biotherapeutics..

Calidi Biotherapeutics (AMEX:CLDI) Stock, Chaîne d'Options

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) with a Buy and lowers the price target from $7 to $5.

News

Price Target

Analyst Ratings

MREO

Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $5

<a href="https://x.com/elonmusk/status/1943251229511160001" title="https://x.com/elonmusk/status/1943251229511160001">https://x.com/elonmusk/status/1943251229511160001</a>

Tech

TSLA

Elon Musk Post on X: Grok is coming to Tesla vehicles very soon. Next week at the latest.

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) announced its <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">net revenue</a> for June 2025 on Thursday.
The leading contract chipmaker reported consolidated revenue of approximately 263.71 billion New Taiwan dollars (approximately $8.3 billion) for the month. This represents a 17.7% decrease from May 2025 but a 26.9% increase <a target="_blank" href="https://pr.tsmc.com/english/news/3246" rel="noreferrer noopener">compared to June 2024</a>.
For the first half of 2025 (January through June), Taiwan Semiconductor&#8217;s total revenue reached 1.773 trillion New Taiwan dollars (approximately $55.8 billion), marking a 40.0% year-over-year increase.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46219423/taiwan-semiconductor-outperforming-the-market-shows-moatbut-it-comes-with-risk" rel="noreferrer noopener">Taiwan Semiconductor Outperforming The Market Shows Moat, But It Comes With Risk</a>
Taiwan Semiconductor&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44732800/taiwan-semiconductor-reports-255-billion-q1-revenue-surges-42-in-despite-us-tensions" rel="noreferrer noopener">second-quarter 2025 revenue</a> reached 933.79 billion New Taiwan dollars (approximately 31.9 billion), based on the reported first−quarter revenue of 839.25 billion New Taiwan dollars ($25.5 billion). This indicates a strong 38.6% year-over-year growth for the second quarter of 2025, topping the company&#8217;s own guidance of $28.4 billion to $29.2 billion issued in April.
Bloomberg analyst Charles Shum <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-10/tsmc-revenue-climbs-39-in-latest-sign-of-ai-spending-boom?sref=TBDibEcD" rel="noreferrer noopener">attributed</a> this performance to robust AI-driven demand from chip designers like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and increasing outsourcing orders from Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). Shum suggests this strong momentum is offsetting softness in the mobile and consumer segments, helping Taiwan Semiconductor remain on track for its 25% annual U.S. dollar sales-growth target. However, he anticipates operating margins may be closer to the lower end of guidance (around 47%) due to the weakening U.S. dollar.
In a related development, Taiwan Semiconductor is reportedly prioritizing its <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46283410/taiwan-semiconductor-shifts-focus-100-billion-usa-expansion" rel="noreferrer noopener">U.S. expansion</a>, accelerating American operations in response to potential chip import tariffs from Washington. This focus has reportedly led to the postponement of a second planned Japanese plant, despite a $20 billion investment plan and $8 billion in pledged support from the Japanese government.
While Chairman C.C. Wei previously cited traffic issues in Kumamoto for early delays, sources suggest the project&#8217;s resumption in Japan is not imminent. In March, Taiwan Semiconductor announced an additional $100 billion investment in U.S. chipmaking, building on the $65 billion announced in April 2024.
Taiwan Semiconductor stock has surged over 17% year-to-date, topping NYSE Composite&#8217;s 8% and PHLX Semiconductor&#8217;s approximately 14%. The stock surged over 53% in the last three months, topping NYSE Composite&#8217;s 12% and PHLX Semiconductor&#8217;s 34%.
Price Action:&nbsp;TSM stock is trading higher by 1.66% to $235.70 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46295574/nvidia-outpaces-market-with-ai-powered-growth" target="_blank" rel="noreferrer noopener">Nvidia Outpaces Market With AI-Powered Growth, Nears Record Highs</a></li>
</ul>
Photo via Shutterstock

Earnings

Media

INTC

NVDA

Taiwan Semiconductor Reports Solid Half-Year Revenue, June Sees Monthly Decline

BeOne Medicines Says European Commission Approves Tevimbra With Chemotherapy As First-Line Treatment For Nasopharyngeal Carcinoma Based On PFS, OS Gains In Phase 3 Study

Personal finance guru Dave Ramsey guided a 28-year-old North Dakota caller away from a courthouse wedding, despite the couple&#8217;s substantial debt burden of $205,000 against their combined $240,000 income.
What Happened: The caller, who referred to his 25-year-old fiancée as his &#8220;old lady,&#8221; sought advice on The Ramsey Show about combining incomes to accelerate debt payoff. He proposed a courthouse ceremony followed by a delayed celebration after becoming debt-free.
&#8220;I want to do it as cheap as possible,&#8221; the caller told Ramsey and co-host Jade Warshaw. &#8220;You are such a guy,&#8221; said Ramsey. 
Ramsey rejected the extreme budget approach. &#8220;You&#8217;re in North Dakota, so you have a chat for the weekend and have a nice weekend in Vegas and spend $3,000 to $4,000 out of 240,&#8221; he advised, suggesting a middle-ground celebration costing roughly 1.7% of their annual income.
Warshaw cautioned against framing the decision purely around debt acceleration. &#8220;I just wanna make sure you&#8217;re doing it because you wanna get married. Not because you wanna pay off debt faster,&#8221; she said, noting the proposal lacked romantic appeal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;I&#39;m thinking about getting married to my old lady&#8230;&quot; <a href="https://t.co/nL1XwRcU7l">pic.twitter.com/nL1XwRcU7l</a>
&mdash; Dave Ramsey (@DaveRamsey) <a href="https://twitter.com/DaveRamsey/status/1942595799776375119?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/25/07/46337678/chamath-palihapitiya-agrees-with-a-social-media-user-who-says-while-meta-spends-200-million-a-year-to-poach-ai-talent-elon-musk-keeps-costs-low-but-still-manages-to-unveil-better-products">Chamath Palihapitiya Agrees With A Social Media User Who Says While Meta Spends $200 Million A Year To Poach AI Talent, Elon Musk Keeps Costs Low But Still Manages To Unveil Better Products</a>
Why It Matters: Ramsey emphasized long-term relationship value over short-term savings. &#8220;I appreciate what you&#8217;re trying to accomplish mathematically. Long-term you&#8217;re gonna tell the story for the rest of your life and it needs to be a better story,&#8221; he said.
The advice aligns with Ramsey&#8217;s established <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/07/46311671/dave-ramsey-values-a-quality-marriage-and-relationship-over-money-he-once-schooled-a-caller-who-hid-money-from-wife-that-spends-too-much">philosophy, prioritizing marriage quality over financial optimization</a>. In previous shows, he has criticized callers who hide assets from spouses or make major relationship decisions based solely on mathematical considerations.
The caller&#8217;s situation reflects broader debt trends among high-income earners. Recent data shows many households earning above $200,000 annually still carry significant consumer debt loads, often exceeding 80% of their income.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46337215/tesla-is-basically-hijacked-by-elon-musk-says-ross-gerber-calling-it-completely-ridiculous-america-party-is-the-worst-news-for-tsla">Tesla Is &#8216;Basically Hijacked&#8217; By Elon Musk, Says Ross Gerber, Calling It &#8216;Completely Ridiculous:&#8217; America Party Is The &#8216;Worst News For TSLA&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Personal Finance

Dave Ramsey Tells Debt-Laden 28-Year-Old To Skip Courthouse Wedding: 'You'll Tell This Story' Forever

IMOS

ChipMOS Q2 Revenue $196.6M Up 3.7% QoQ, June Sales Fall 8.7% MoM to $63.4M; Memory Demand Drives Quarterly Gain

SLNO

Soleno Therapeutics Reports Preliminary Q2 Results With VYKAT XR Net Revenue Between $31M–$33M, Ends Quarter With $293.8M In Cash

BIT Mining Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) ("BIT Mining" or the "Company"), a leading technology-driven cryptocurrency mining company, today announced a strategic shift with its expansion into the Solana ecosystem, marking a critical milestone in the Company's long-term growth trajectory. This transition positions BIT Mining&nbsp;to capture emerging opportunities across the broader blockchain value chain, while also attracting&nbsp;investors seeking exposure to the Solana ecosystem. By entering the Solana ecosystem, the Company aims to leverage its high-performance infrastructure and dynamic developer community to drive innovation, enhance ecosystem integration, and create sustainable shareholder value.
As part of this strategic realignment, BIT Mining will build a robust SOL treasury as a core pillar of its strategic shift. To support its Solana-focused strategy, the Company plans to raise between $200M and $300M in phases, based on market conditions and capital availability. Proceeds will be used to accumulate SOL&nbsp;tokens, strengthening the Company's&nbsp;treasury reserves through ongoing capital deployment and incremental acquisitions.
To initiate the treasury, BIT Mining&nbsp;will convert its existing crypto holdings into SOL and adopt a long-term holding strategy. Looking ahead, the Company intends to further capitalize on its market expertise and proprietary technologies by deepening its participation in the Solana ecosystem, including operating validator nodes to support network decentralization and security, while generating stable, on-chain staking rewards.&nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

BTCM

BIT Mining Bets Big on Solana, Plans Up to $300M Investment to Build Long-Term Crypto Treasury

MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) ("MP Materials" or the "Company") today announced it has entered into a transformational public-private partnership with the United States Department of Defense ("DoD") to dramatically accelerate the build-out of an end-to-end U.S. rare earth magnet supply chain and reduce foreign dependency.
With a multibillion-dollar package of investments and long-term commitments from DoD, MP Materials will construct the Company's second domestic magnet manufacturing facility (the "10X Facility") at a soon-to-be-chosen location to serve both defense and commercial customers. Once the new facility is completed, expected to begin commissioning in 2028, MP Materials' total U.S. rare earth magnet manufacturing capacity will reach an estimated 10,000 metric tons.
The Company also expects to add additional heavy rare earth separation capabilities at its Mountain Pass, California, facility, solidifying its status as a national strategic asset where high-purity rare earth materials are extracted, separated and refined all in one location.
"This initiative marks a decisive action by the Trump administration to accelerate American supply chain independence," said James Litinsky, Founder, Chairman, and CEO of MP Materials. "We are proud to enter into this transformational public-private partnership and are deeply grateful to President Trump, our partners at the Pentagon, and our employees, customers and stakeholders for their unwavering support and dedication."
Rare earth magnets are one of the most strategically important components in advanced technology systems spanning defense and commercial applications. Yet today, the U.S. relies almost entirely on foreign sources. This strategic partnership builds on MP Materials' operational foundation to catalyze domestic production, strengthen industrial resilience, and secure critical supply chains for high-growth industries and future dual use applications.
The agreements comprise a comprehensive, long-term package – including convertible preferred equity, warrants, loans, and price floor and offtake commitments – that extend for more than a decade.
<ul>
<li>DoD has entered into a 10-year agreement establishing a price floor commitment of $110 per kilogram for MP Materials' NdPr products stockpiled or sold, reducing vulnerability to non-market forces and ensuring stable and predictable cash flow with shared upside.</li>
<li>For a period of 10 years following the construction of the 10X Facility, DoD has agreed to ensure that 100% of the magnets produced at the 10X Facility will be purchased by defense and commercial customers with shared upside.</li>
<li>The Company has obtained a commitment letter from JPMorgan Chase Funding Inc. and Goldman Sachs Bank USA to provide $1.0 billion of financing for the costs of constructing and developing the 10X Facility, subject to customary terms and conditions set forth therein. In addition, within 30 days, the Company expects to receive the proceeds of a $150 million loan from DoD in connection with its plan to expand its heavy rare earth separation capabilities at Mountain Pass.</li>
<li>As part of the agreement, DoD agreed to purchase $400 million of a newly-created series of the Company's preferred stock convertible into shares of the Company's common stock, and a warrant permitting DoD to purchase additional shares of the Company's common stock. The initial conversion price and exercise price are $30.03 per share of common stock. The purchase is scheduled to close on July 11, 2025. The Company intends to use the proceeds of this investment to expand its existing rare earths separation and processing capabilities, as well as its magnet production capacity.</li>
<li>As a result of the strategic investment, DoD is positioned to become the Company's largest shareholder. On an as-converted and as-exercised basis, the convertible preferred stock and the warrant represent, in the aggregate, 15% of the Company's issued and outstanding shares of common stock as of July 9, 2025, without giving effect to the issuance of such shares.</li>
</ul>
MP Materials currently operates the world's second-largest rare earth mine in Mountain Pass, California, where it extracts, refines, and separates rare earth materials. The Company is commissioning a magnetics facility in Texas, known as Independence, which anchors its downstream capabilities.

Government

Regulations

MP Materials Strikes $Billion Deal With Pentagon to Build US Rare Earth Magnet Supply Chain

Needham analyst John Todaro downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Hold and maintains the price target from $18 to $18.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

Needham Downgrades Core Scientific to Hold, Maintains Price Target to $18

CLEAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>), an official TSA PreCheck&#xAE; enrollment provider, is participating in the Transportation Security Administration's (TSA) Serve with Honor, Travel with Ease initiative to provide discounted TSA PreCheck enrollment fees for military spouses and free enrollment for family members of service members who died in the line of duty or as a result of service-connected injury or illness–referred to as Gold Star families.
A $25 enrollment discount will be applied for spouses of currently serving uniformed service members—recognizing the frequent travel burdens tied to military life. Additionally, Gold Star families will receive free TSA PreCheck–a tribute to those who have lost loved ones in military service.
"At CLEAR, we believe in showing up for people who show up for all of us," said Caryn Seidman Becker, CEO of CLEAR. "We're proud to support the TSA's Serve with Honor, Travel with Ease initiative by making it easier for military families to access the benefits of TSA PreCheck. Whether it's a military spouse managing multiple moves or a Gold Star family traveling in memory of a loved one, we're honored to make predictable travel more accessible for military families."
Additionally, CLEAR is bringing mobile enrollment units to major military installations, reducing travel burdens for eligible families. This effort ensures that enrollment is as accessible as possible, especially for families living on or near military bases.

CLEAR Offers Discounted TSA PreCheck for Military Spouses, Free Access for Gold Star Families

Yoshitsu Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) reported quarterly earnings of $0.19 per share. This is a 5 percent decrease over earnings of $0.20 per share from the same period last year. The company reported $210.119 million in sales this quarter. This is a 7.38 percent increase over sales of $195.681 million the same period last year.

TKLF

Yoshitsu Co FY EPS $0.19 Down From $0.20 YoY, Sales $210.119M Up From $195.681M YoY

Modivcare Inc. (the "Company" or "Modivcare") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced it has regained compliance with Rule 5450(b)(3)(C) of the Nasdaq Stock Market LLC ("Nasdaq") regarding the Company's market value of publicly held shares ("MVPHS").
On July 7, 2025, the Company received confirmation from Nasdaq that it regained compliance with the MVPHS requirement for continued listing on Nasdaq, having confirmed that the Company's MVPHS had been above $15 million for at least the last 20 consecutive business days. Accordingly, the Company again satisfies all Nasdaq listing standards required for continued listing on The Nasdaq Global Select Market.

MODV

Modivcare Stock Clears Nasdaq Listing Hurdle After Regaining $15M Public Share Value

Needham analyst Mike Cikos downgrades CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) from Buy to Hold and maintains the price target from $78 to $78.

CRWV

Needham Downgrades CoreWeave to Hold, Maintains Price Target to $78

Keybanc analyst Craig Mailman upgrades National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) from Sector Weight to Overweight and announces $80 price target.

Upgrades

Keybanc Upgrades National Health Investors to Overweight, Announces $80 Price Target

Piper Sandler analyst Brent Bracelin downgrades Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Neutral to Underweight and lowers the price target from $255 to $235.

WDAY

Piper Sandler Downgrades Workday to Underweight, Lowers Price Target to $235

Piper Sandler analyst Brent Bracelin upgrades Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) from Neutral to Overweight and raises the price target from $190 to $270.

ORCL

Piper Sandler Upgrades Oracle to Overweight, Raises Price Target to $270

Keybanc analyst Justin Patterson upgrades Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Sector Weight to Overweight and announces $115 price target.

ROKU

Keybanc Upgrades Roku to Overweight, Announces $115 Price Target

Shares of WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) rose sharply in today's pre-market trading following a WSJ report <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46332395/wk-kellogg-stock-pops-50-on-potential-3-billion-acquisition">suggesting Ferrero is nearing a deal to acquire the company.</a>
Family-owned Italian candy company Ferrero is closing in on a deal to acquire cereal maker WK Kellogg for roughly $3 billion, according to a Wall Street Journal report. People familiar with the matter reportedly said a deal could be completed as soon as this week.
WK Kellogg shares jumped 50.2% to $26.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Steakholder Foods Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKH#NASDAQ">STKH</a>) surged 137.6% to $4.16 in pre-market trading.</li>
<li>GIBO Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) climbed 51.4% to $0.0512 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) rose 51.1% to $20.00 in pre-market trading as the company posted better-than-expected second-quarter results.</li>
<li>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) jumped 51.1% to $0.5550 in pre-market trading after gaining 15% on Wednesday. IGC Pharma has been making significant strides in its field. In June, the company highlighted its fiscal year 2025 with clinical progress and Alzheimer's drug development advances. This included the presentation of a scientific poster titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) gained 43.1% to $1.96 in pre-market trading as the company was granted FDA Orphan Drug designation for KLTO-202 for the treatment of amyotrophic lateral sclerosis. </li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 37.4% to $0.0831 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 29.4% to $0.9000 in pre-market trading. Pop Culture Group, a China-based company focused on developing and hosting hip-hop and other entertainment events, completed a private placement on July 4, 2025.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) gained 15% to $7.01 in pre-market trading after climbing 18% on Wednesday.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) gained 13.8% to $4.94 in pre-market trading as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) dipped 36.6% to $1.87 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Creative Medical Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares tumbled 25.3% to $2.93 in pre-market trading. Creative Medical Technology has received a notice of allowance for a U.S. patent titled &#8220;Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.&#8221;</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 21.3% to $32.50 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) dipped 17.2% to $3.00 in pre-market trading after gaining 99% on Wednesday.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 15.1% to $8.74 in pre-market trading after the company reported a fourth-quarter adjusted EPS miss.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 13.2% to $1.26 in pre-market trading.</li>
<li>Delixy Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLXY#NASDAQ">DLXY</a>) declined 11.4% to $4.38 in pre-market trading after gaining 24% on Wednesday.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 11% to $1.79 in pre-market trading after dipping 20% on Wednesday.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) shares fell 10.5% to $5.89 in pre-market trading after gaining over 56% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 7.7% to $61.60 in pre-market trading. BitMine Immersion Technologies shares dipped 40% on Wednesday after the company filed for a mixed shelf.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo via Shutterstock

AEMD

BMGL

BMNR

CELZ

CPOP

DLXY

GIBO

KLTO

NCNA

NRIX

POET

PROK

RARE

SCAG

STKH

WOLF

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket

Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) announced Thursday that it has entered into a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46335450/kraft-heinz-announces-agreement-to-sell-italian-baby-and-specialty-food-business-to-italys-newprin" rel="noreferrer noopener">definitive agreement to divest</a> its infant and specialty food portfolio in Italy to NewPrinces Group, one of the region&#8217;s top food and beverage producers. The financial terms of the deal were not disclosed.
The sale includes well-known brands, Plasmon, Nipiol, Dieterba, Aproten, and Biaglut, and a manufacturing plant in Latina, Italy. The deal is expected to close by the end of 2025, pending regulatory approval.
Willem Brandt, President of Europe and Pacific Developed Markets at Kraft Heinz, said the move is designed to sharpen the company&#8217;s focus on core categories such as ketchup, sauces, and condiments, which continue to drive growth under the company&#8217;s Accelerate strategy.
Also Read:<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46097002/kraft-heinz-analyst-longer-bearish-amid-review-strategic-alternatives" rel="noreferrer noopener"> This Kraft Heinz Analyst Is No Longer Bearish Amid Review Of Strategic Alternatives</a>
The Latina facility, which produces approximately 1.8 billion biscuits annually and employs 300 workers, will remain operational under NewPrinces&#8217; ownership. Kraft Heinz said it remains committed to the Italian market and plans to grow its HEINZ product lineup across consumer and foodservice channels.
Carmela Bazzarelli, Managing Director of Kraft Heinz Italia, voiced confidence in NewPrinces&#8217; stewardship of the acquired assets, citing the buyer&#8217;s experience in nutrition and deep roots in the Italian food industry.
NewPrinces, previously known as Newlat Food, broadened its portfolio after acquiring Princes Limited in 2024. Its offerings include brands such as Napolina, Branston, Flora, and Delverde, with distribution spanning the UK and European markets.
KHC has initiated mandatory consultations with labor unions in Italy.
Last month, Kraft Heinz <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45980305/kraft-heinz-bans-artificial-colors-in-us-products-eyes-full-phaseout-by-2027" rel="noreferrer noopener">announced</a> it would stop launching U.S. products with synthetic FD&amp;C colors and entirely remove them by 2027. With nearly 90% of its lineup already free of such dyes, the move aligns with growing demand for cleaner labels. The initiative reinforces the company&#8217;s long-term shift toward healthier, consumer-preferred ingredients.
Investors may also track relevant ETFs, such as the Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) and the iShares U.S. Consumer Goods ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>).
Price Action: KHC shares are trading higher by 0.19% to $26.50 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46336626/trump-administration-sues-gavin-newsom-other-state-officials-over-californias-egg-laws-driving-up-prices-nationwide-unnecessary-red-tape" target="_blank" rel="noreferrer noopener">Trump Administration Sues Gavin Newsom, Other State Officials Over California&#8217;s Egg Laws Driving Up Prices Nationwide: &#8216;Unnecessary Red Tape&#8217;</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Asset Sales

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

Kraft Heinz Sells Italian Infant Food Business

Press Releases

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Health Care

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy  Platform at AACR Annual Meeting

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Small Cap

Opinion

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

General

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Financing

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

CGON

CLDI

CRSP

CTMX

IBRX

MTEM

REGN

RHHBF

RHHBY

VRTX

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Calidi Biotherapeutics, Inc. Common Stock

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

Elevation Oncology

FibroGen

Generation Bio

Geovax Labs

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

MEI Pharma

Marker Therapeutics

NuCana

Nanoviricides

OSR Holdings

Plus Therapeutics

Q32 Bio

Rallybio

SAB Biotherapeutics

Tenax Therapeutics

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Calidi Biotherapeutics

Calidi Biotherapeutics (CLDI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL